Two co-primary outcomes <br/ >1. Frequency of RTPCR negativity at day 5 after drug administration <br/ >2. Change in viral load (as determined by RTPCR cycle threshold) at day 5 as compared to baselineTimepoint: Day 5 after drug administration

Two co-primary outcomes <br/ >1. Frequency of RTPCR negativity at day 5 after drug administration <br/ >2. Change in viral load (as determined by RTPCR cycle threshold) at day 5 as compared to baselineTimepoint: Day 5 after drug administration

N/A

N/A

Two co-primary outcomes <br/ >1. Frequency of RTPCR negativity at day 5 after drug administration <br/ >2. Change in viral load (as determined by RTPCR cycle threshold) at day 5 as compared to baselineTimepoint: Day 5 after drug administration

Two co-primary outcomes <br/ >1. Frequency of RTPCR negativity at day 5 after drug administration <br/ >2. Change in viral load (as determined by RTPCR cycle threshold) at day 5 as compared to baselineTimepoint: Day 5 after drug administration

To evaluate the efficacy of different doses of single dose ivermectin in reducing viral load as estimated by cycle threshold of nasopharyngeal/oropharyngeal RTPCR at Day 4 in patients with COVID19Timepoint: Day 4 after drug administration

To evaluate the efficacy of different doses of single dose ivermectin in reducing viral load as estimated by cycle threshold of nasopharyngeal/oropharyngeal RTPCR at Day 4 in patients with COVID19Timepoint: Day 4 after drug administration